Pancreatic Cancer Survivorship: Follow-Up Questions

Most pancreatic cancer follow-up is about two separate things at once. One is watching for the cancer. The other is managing an organ that has been cut, irradiated, or both.

Those two jobs get mixed together at appointments. Separating them makes the visit more useful, because the questions and the people who answer them are different.

CA 19-9 is the blood test that gets watched. NCI's summary describes what it can do in unusually plain terms.

No tumor-specific markers exist for pancreatic cancer. Markers such as CA 19-9 have low specificity. Most people with pancreatic cancer have an elevated CA 19-9 at diagnosis. Increased levels during or after definitive therapy may identify progressive tumor growth.

Then comes the sentence that matters most after treatment. The presence of a normal CA 19-9 level does not preclude recurrence.

Both halves are worth holding. A rising number is information. A normal number is not reassurance. Some tumors do not make the protein at all, and other conditions, including bile duct blockage, can raise it without any cancer. The trend across several readings carries more meaning than any single value.

This is worth stating openly rather than filling in with a plausible-sounding number.

NCI's pancreatic cancer treatment summary does not set a follow-up schedule. It names no interval for scans, no interval for CA 19-9, and no total duration.

What NCI does publish is general. Across cancers, people usually return every 3 to 4 months during the first 2 to 3 years after treatment, and once or twice a year after that. The summary is explicit that each schedule differs, and depends on the cancer type, the treatment given, and the person's health.

So the correct question is not what the standard interval is. It is what schedule this particular team has set, and what it is looking for at each visit. Getting that written into a survivorship care plan is the point of the document.

The pancreas does two unrelated jobs. It makes digestive enzymes, and it makes insulin. Surgery and disease can damage either.

NCI names the first problem directly. Malabsorption caused by exocrine insufficiency frequently contributes to malnutrition. Pancreatic enzyme replacement can help relieve it.

That is a treatable problem that often goes unmentioned, because its signs read as ordinary recovery. Weight that keeps falling. Stools that are loose, pale, greasy, or hard to flush. Bloating after fatty meals. Those are enzyme problems, and the dose of replacement enzyme is adjustable.

Blood sugar is the second half. Removing part of the pancreas removes insulin-producing tissue with it, so glucose deserves checking rather than assuming.

Weight itself is a working measurement here, not a cosmetic one. It shapes what treatment would be tolerable if any is ever needed again.

For people who had surgery followed by chemotherapy, the trial behind that decision is worth knowing, because its side effects can persist.

PRODIGE-24 randomized 493 people with R0 or R1 resections. One arm had six cycles of gemcitabine. The other had 12 cycles of FOLFIRINOX, a four-drug combination of oxaliplatin, leucovorin, irinotecan, and fluorouracil, given into a vein every 2 weeks with the fluorouracil running over about two days. The amounts are worked out from body size by the treating team, so they are not listed here.

Median disease-free survival was 21.4 months with FOLFIRINOX against 12.8 with gemcitabine. Median overall survival was 53.5 months against 35.5. Five-year overall survival was 43.2% against 31.4%.

The cost side is equally specific. Grade 3 or 4 toxicity occurred in 75.9% of the FOLFIRINOX group against 52.9% of the gemcitabine group. Thirty-three percent stopped FOLFIRINOX early, against 21% for gemcitabine.

Oxaliplatin-related numbness in the hands and feet is the effect most likely to still be present at follow-up visits. It is worth raising, since it is graded and tracked rather than simply endured.

Two NCI-affiliated sources give different numbers here, and the gap is large enough to name.

The pancreatic cancer PDQ summary states an overall survival rate of less than 6%. SEER, which is also run by NCI, reports 5-year relative survival of 13.7% for 2016 to 2022, and 43.6% for cancer that was still localized at diagnosis.

The SEER figure is the more current one. Anyone reading the older number should know a newer one exists.

A few problems after pancreatic surgery have specific, treatable causes, and NCI names the tools for them in its palliative section.

Jaundice, dark urine, and pale stools point to a blocked bile duct. NCI lists surgical or radiological biliary decompression as a palliative measure, and elsewhere names endoscopic, surgical, or radiological relief of biliary obstruction. It is a mechanical problem with a mechanical fix.

Pain in the upper abdomen radiating to the back is the second. NCI lists pain control as a distinct treatment goal in this disease, separate from treating the tumor.

Fever after any biliary procedure belongs in the same-day category, because an obstructed, infected duct does not improve on its own.

Follow-up care after this disease usually involves more than an oncologist. A dietitian handles the enzyme dosing and weight. A primary care doctor keeps routine care going, which NCI emphasizes should continue alongside cancer follow-up. Notes need to move between them, and NCI notes that research has found tests and treatments from one doctor are not always shared with another.

For related ground, see pancreatic cancer, watching for cancer recurrence, and fear of recurrence.

• NCI PDQ — Pancreatic Cancer Treatment (Health Professional Version)
• NCI — Follow-Up Medical Care
• SEER Cancer Stat Facts — Pancreatic Cancer